Rodman & Renshaw initiated coverage of Kyntra Bio (NASDAQ: KYNB) with a “buy” rating and price target of $30.00. The stock closed at $6.63 on June 8.
Kyntra Bio (formerly known as FibroGen) is a biopharmaceutical company focused on the development of novel therapies in oncology and rare disease. Roxadustat (EVRENZO) is currently approved in Europe, Japan, China, and numerous other countries for the treatment of anemia in chronic kidney disease (CKD) patients on dialysis and not on dialysis. The Company continues to evaluate the development plan for the Phase 3 trial of roxadustat in anemia associated with lower-risk myelodysplastic syndromes (LR-MDS) in the U.S. FG-3246 (also known as FOR46), a first-in-class antibody-drug conjugate (ADC) targeting CD46, is in Phase 2 development for the treatment of metastatic castration-resistant prostate cancer. This program also includes the development of FG-3180, an associated CD46-targeted PET biomarker.
“Kyntra Bio is the product of one of the more skillfully executed corporate transformations in recent small-cap biotech,” writes Rodman & Renshaw analyst Michael G. King, Jr. “The legacy FibroGen platform was burdened by an oversized China commercial operation, a complex capital structure, and significant going-concern issues that consumed management bandwidth and obscured the genuine scientific value embedded in its pipeline. Add this to the challenging equation of the denial of approval by the U.S. FDA of roxadustat for the treatment of CKD in 2021, and the former FibroGen turned into a biotech train wreck after an extremely promising beginning. The sale of FibroGen China to AstraZeneca (AZN, NC) for approximately $220 million was not merely a divestiture; it was the surgical removal of a structural drag on enterprise value that simultaneously funded a cleaner balance sheet and allowed management to concentrate entirely on two US development programs with legitimate blockbuster potential. The repayment of the Tactical Value term loan eliminated the most significant financing overhang, and the rebranding to Kyntra Bio in January 2026 signaled a cultural and strategic reset that is still not fully reflected in the equity price, despite a cash runway into 2028 and a lean operating structure with zero commercial distraction.”
“At current valuation levels, the market continues to price Kyntra as though neither [the Roxadustat nor FG-3246 programs have] meaningful probability of success and as though the corporate transformation created little incremental value,” contends Mr. King.
“We find that assessment difficult to defend against the weight of the clinical evidence and the balance sheet strength. The 4Q26 FG-3246 interim readout, combined with potential visibility on roxadustat Phase 3 initiation, offers a concentrated near-term catalyst window that could materially re-rate the stock.”
